Amphastar Pharma (AMPH) Tops Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2019
May 9, 2019 4:07 PM EDTReports Net Revenues of $79.8 Million for the Three Months Ended March 31, 2019
RANCHO CUCAMONGA, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (Amphastar or the Company) today reported results for the three months ended March 31, 2019.
First Quarter Highlights
Net revenues of $79.8 million for the first quarterGAAP net income of $0.9 million, or $0.02 per share, for the first quarterAdjusted non-GAAP net income of $4.9 million, or $0.10 per share, for the first quarterDr. Jack Zhang, Amphastars Chief Executive Officer, commented:Â We... More
